Neurocrine Biosciences Receivables 2010-2024 | NBIX

Neurocrine Biosciences receivables for the quarter ending September 30, 2024 were $0.481B, a 15.15% increase year-over-year.

  • Neurocrine Biosciences receivables for 2023 were $0.439B, a 25.51% increase from 2022.
  • Neurocrine Biosciences receivables for 2022 were $0.35B, a 88.68% increase from 2021.
  • Neurocrine Biosciences receivables for 2021 were $0.186B, a 18.08% increase from 2020.

Neurocrine Biosciences Receivables 2010-2024 | NBIX

  • Neurocrine Biosciences receivables for 2023 were $0.439B, a 25.51% increase from 2022.
  • Neurocrine Biosciences receivables for 2022 were $0.35B, a 88.68% increase from 2021.
  • Neurocrine Biosciences receivables for 2021 were $0.186B, a 18.08% increase from 2020.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$79.2B
Takeda Pharmaceutical (TAK)$43.3B
Sandoz Group AG (SDZNY)$19.5B
Merck (MKKGY)$19.2B
Astellas Pharma (ALPMY)$18.2B
United Therapeutics (UTHR)$16.1B
Summit Therapeutics (SMMT)$14.7B
Shionogi (SGIOY)$11.9B
Catalent (CTLT)$10.7B
Jazz Pharmaceuticals (JAZZ)$7.1B
Madrigal Pharmaceuticals (MDGL)$6.9B
Orion OYJ (ORINY)$6.7B
Corcept Therapeutics (CORT)$5.7B
Ionis Pharmaceuticals (IONS)$5.3B
Crinetics Pharmaceuticals (CRNX)$5.1B
PTC Therapeutics (PTCT)$3B
Dyne Therapeutics (DYN)$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.6B
Arrowhead Pharmaceuticals (ARWR)$2.3B
Soleno Therapeutics (SLNO)$2.2B
NewAmsterdam Pharma (NAMS)$2.2B
Centessa Pharmaceuticals (CNTA)$1.9B
Evotec AG (EVO)$1.8B
Recursion Pharmaceuticals (RXRX)$1.8B
Xencor (XNCR)$1.7B
BioCryst Pharmaceuticals (BCRX)$1.5B
Indivior (INDV)$1.4B
Harrow (HROW)$1.4B
Ocular Therapeutix (OCUL)$1.4B